Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Return on Capital Employed: 2021-2023

Historic Return on Capital Employed for Candel Therapeutics (CADL) over the last 2 years, with Sep 2023 value amounting to -0.82%.

  • Candel Therapeutics' Return on Capital Employed fell 41.00% to -0.82% in Q3 2023 from the same period last year, while for Sep 2023 it was -0.82%, marking a year-over-year decrease of 41.00%. This contributed to the annual value of -0.45% for FY2022, which is 1.00% down from last year.
  • According to the latest figures from Q3 2023, Candel Therapeutics' Return on Capital Employed is -0.82%, which was down 24.34% from -0.66% recorded in Q2 2023.
  • In the past 5 years, Candel Therapeutics' Return on Capital Employed registered a high of -0.29% during Q4 2021, and its lowest value of -0.82% during Q3 2023.
  • Over the past 3 years, Candel Therapeutics' median Return on Capital Employed value was -0.41% (recorded in 2022), while the average stood at -0.48%.
  • Data for Candel Therapeutics' Return on Capital Employed shows a maximum YoY crashed of 41bps (in 2023) over the last 5 years.
  • Candel Therapeutics' Return on Capital Employed (Quarterly) stood at -0.29% in 2021, then decreased by 16bps to -0.46% in 2022, then crashed by 41bps to -0.82% in 2023.
  • Its Return on Capital Employed stands at -0.82% for Q3 2023, versus -0.66% for Q2 2023 and -0.53% for Q1 2023.